Respiratory infections: a current and future threat.
Despite all the medical progress in the last 50 years pulmonary infections continue to exact and extremely high human and economic cost. This review will focus on the human, pathogen and environmental factors that contribute to the continued global burden or respiratory diseases with a particular focus on areas where we might hope to see some progress in the coming decades.
Waterer
Grant
G
Centre for Asthma, Allergy and Respiratory Research, School of Medicine and Pharmacology, University of Western Australia, Level 4 MRF Building, Royal Perth Hospital, GPO Box X2213, Perth, WA 6847, Australia. grant.waterer@uwa.edu.au
Wunderink
Richard
R
D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D017048:Health Care Costs; D006801:Humans; D015995:Prevalence; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology*
D000900:Anti-Bacterial Agents; D000998:Antiviral Agents